Cardiovascular outcomes of sodium-glucose co-transporter-2 inhibitors in heart failure and coexisting chronic obstructive pulmonary disease: A meta-analysis

doi:10.4330/wjc.119509

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 6

This Article

(2)

(0)

(17)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Cardiol. Jun 26, 2026; 18(6): 119509
Published online Jun 26, 2026. doi: 10.4330/wjc.119509

Table 1 Studies included in the review

Ref.	Study region	Type of study	Total study population	Study group (n)	Control group (n)	Sodium-glucose co-transporter-2 inhibitor used
Haehling et al[3]	United States	RCT	1238	614	624	Empagliflozin 10 mg
Anker et al[4]	United States	RCT	707	462	245	Empagliflozin 10 mg
Butt et al[5]	United States	RCT	694	352	342	Dapagliflozin 10 mg
Dewan et al[6]	United States	RCT	585	299	286	Dapagliflozin 10 mg

RCT: Randomized controlled trial.

Full Size Table

Citation: Khan ZA, Sohail R, Khattak R, Patel V, Alberto Jr M, Anand P, Feldiorean A, Georgy M, Valdiviez LM, Poldneff D, Khan Z, Murtaza I, Curry S. Cardiovascular outcomes of sodium-glucose co-transporter-2 inhibitors in heart failure and coexisting chronic obstructive pulmonary disease: A meta-analysis. World J Cardiol 2026; 18(6): 119509
URL: https://www.wjgnet.com/1949-8462/full/v18/i6/119509.htm
DOI: https://dx.doi.org/10.4330/wjc.119509

Khan ZA, Sohail R, Khattak R, Patel V, Alberto Jr M, Anand P, Feldiorean A, Georgy M, Valdiviez LM, Poldneff D, Khan Z, Murtaza I, Curry S. Cardiovascular outcomes of sodium-glucose co-transporter-2 inhibitors in heart failure and coexisting chronic obstructive pulmonary disease: A meta-analysis. World J Cardiol 2026; 18(6): 119509 [DOI: 10.4330/wjc.119509]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.